Buclizine 是具有口服活性的抗组胺、抗过敏化合物。Buclizine 是大鼠的强致畸剂，并具有抗肿瘤活性。
| 生物活性 | Buclizine is an orally activeantihistamineantiallergic compound. Buclizine is a potent teratogen in the rat and shows anti-tumor activity[1][2][3]. |
体外研究
(In Vitro) | Buclizine (0.1-100 μM; 72 h) inhibits growth of MCF-7 cells[2].
Buclizine (9.625-77 μM; 72 h) arrests the cell cycle in the G1 phase in a dose-dependent manner[2].
Buclizine (0-75 μM; 72 h) decreases TCTP (translationally controlled tumor protein) and cell cycle regulatory proteins expression in MCF-7 cells, increases pro-apoptotic MCL-1S expression[2].
Cell Proliferation Assay[2] | Cell Line: | MCF-7 cells | | Concentration: | 0-100 μM | | Incubation Time: | 72 hours | | Result: | Showed considerable growth inhibition (IC50=19.18 μM). |
Cell Cycle Analysis[2] | Cell Line: | MCF-7 cells | | Concentration: | 9.625, 19.25, 38.5, and 77 μM | | Incubation Time: | 72 hours | | Result: | Increased the percentages of cells in the G1 phase to 73% at 77 μM. |
Western Blot Analysis[2] | Cell Line: | MCF-7 cells | | Concentration: | 0-75 μM | | Incubation Time: | 72 hours | | Result: | Decreased TCTP expression by 40% at 75 μM.
Decreased cyclin D1, cyclin D3, CDK2 and CDK4 expression after 72 h. |
|
体内研究
(In Vivo) | Buclizine dihydrochloride (30-200 mg/kg; tenth to fifteenth and twelfth to fifteenth days of gestation) shows potent teratogens in the rat[3].
| Animal Model: | Eighty-seven mature female rats weighing 240±20 grams[3] | | Dosage: | 30, 40, 60, 100, and 200 mg/kg | | Administration: | 30-200 mg/kg; tenth to fifteenth and twelfth to fifteenth days of gestation | | Result: | Resulted in malformations in 100% of the young at a dose level of 60-100 mg/kg. |
|
| 分子量 | |
| Formula | |
| CAS 号 | |
| 中文名称 | |
| 运输条件 | Room temperature in continental US; may vary elsewhere. |
| 储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |
m.cnreagent.com